Multiple sclerosis (MS) is a demyelinating, progressive and neurodegenerative disease. A disturbance on the hypothalamic-pituitaryadrenal axis can be observed in patients with MS, showing altered cortisol levels. We aimed to identify basal cortisol levels and verify the relationship with clinical symptoms in patients with MS. A systematic search was conducted in the databases: Pubmed, Web of Science and SCOPUS. Both higher and lower cortisol levels were associated with MS. Higher cortisol levels were associated with depression and anxiety, while lower levels were associated with depression, fatigue and urinary dysfunction. Higher cortisol levels may be associated with the progression and severity of MS.
Multiple sclerosis (MS) is a progressive and inflammatory neurodegenerative disease, characterized by demyelinating lesions and atrophy, in the central nervous system (CNS) 1,2,3 . It affects 1/1,000 people in the western world and leads to chronic disability in young adults ranging between 20 and 40 years old 4 . Multiple sclerosis presents an unpredictable and often progressive course, with many neurological symptoms 5 , which include sensory disorders 6 , visual problems 7 , fatigue 8 , alterations in balance 9 , dysfunction of the lower urinary tract 10 , limitations in walking 11 and cognitive dysfunction 12 .
The etiology of MS is considered multifactorial and involves genetic and environmental mechanisms, which affect the immunological response 13 . Although the origin is still unknown, autoimmune mechanisms are considered central triggers of MS 14 . A widely-accepted model considers MS to be an autoimmune chronic inflammation, mediated by T-cells and macrophages infiltrating the CNS through the peripheral immunological system, which is involved in myelin sheath destruction along with microglia 10, 15 . Nowadays B-cells are getting a great deal of attention as well.
It has been demonstrated that alterations in the neuroendocrine system may also be involved in immune suppression or activation, increasing the vulnerability and severity of autoimmune diseases such as MS 4, 16, 17 . In this context, several studies have indicated that there is a role of the hypothalamic-pituitary-adrenal (HPA) axis in the control of MS progression 18 . In physiological conditions, the HPA axis releases glucocorticoids able to mediate the expression of inflammatory genes of cytokines, action of monocytes and macrophages, and adhesion and migration molecules, which have immunomodulatory effects 19, 20 . In patients with MS, activation of the HPA axis appears to be dysregulated, and chronic hyperactivity occurs in about 50% of the patients 14, 18, 21, 22 . The reactivity of the HPA axis has been correlated with MS progression and global increase in the activation of the neurodegenerative process 21, 23, 24 .
Cortisol is an end-product glucocorticoid of the HPA axis in humans, considered to be the stress hormone and a powerful natural immunosuppressant, involved in regulatory functions such as in glucose metabolism, insulin release, arterial pressure, immune and inflammatory responses 4, 25 . In MS, as a consequence of the disrupted HPA axis, cortisol levels become altered. In patients with MS, the cortisol response after intravenous administration of corticotrophin-releasing hormone is higher, when compared with healthy adult subjects 26, 27, 28 . This increase of the cortisol response was associated both positively 29 , and negatively 30 , with the number of acute lesions due to central neuroinflammation in MS.
In several studies, higher levels of basal cortisol were observed in the cerebrospinal fluid (CSF) and blood, as well as an increase in the cortisol awakening response measured in saliva 5, 25, 30, 31, 32, 33 . As well, evidence in postmortem humans showed that higher levels of cortisol in the CSF are neuroprotective while lower levels are related to a higher number of lesions 30 .
Physiologically, cortisol release levels and the activated cerebral regions depend on the type of stress factor, where motor stress has been associated with brainstem activation while psychological stress has been associated with limbic regions 34 . In MS, some studies have investigated the relationship between cortisol levels and symptoms that arise during the course of the disease; however, there is still no consensus about the role of cortisol as a cause or consequence of the symptoms. Current evidence is directed, mainly, to the relationship of cortisol with fatigue and depression, which are the most common symptoms in MS 35, 36 .
In affective symptoms, such as anxiety and depression, significant correlations are found with higher levels of cortisol, especially in patients suffering from relapsing-remitting multiple sclerosis (RRMS) 5, 29, 37 . Furthermore, studies have shown that cortisol is correlated with fatigue and might have an important role in RRMS 25, 38 . Nevertheless, contradictory results have also been observed, where MS patients with depression and chronic fatigue showed cortisol levels with no increase or significant correlations 39, 40, 41 .
Even though several investigations have considered the role of the HPA axis in MS, there is still little consensus about the cortisol levels and their role in MS pathophysiology. In this study, we aimed to investigate basal cortisol levels in MS and the methods of cortisol evaluation, though a systematic review. Moreover, we intended to verify whether cortisol levels were related to clinical symptoms observed in multiple sclerosis.
METHODS
The systematic review was performed on the results of the database searches from January to March in 2018, which were conducted according to PRISMA guidelines 42 . The articles were selected from three databases: PubMed, Web of Science and SCOPUS. To find representative articles, the following keywords were input: [multiple sclerosis AND cortisol]; [multiple sclerosis AND cortisol AND progression]; [multiple sclerosis AND stress AND cortisol]; [multiple sclerosis AND cortisol AND progression AND stress].
The selected articles in this review were assessed independently by two evaluators and met the following criteria: 1) the sample comprised only humans ( from 18 years of age); 2) the articles were published between 2006 and 2017; 3) patients had been affected only by MS, with no neurological diseases from other etiologies; 4) cortisol had been assessed from urine, blood, CSF, saliva or hair; 5) there was an assessment of any physical, behavioral and/or cognitive symptom; 6) the full text of the article was available in the database; 7) the full article was in English. Articles were excluded from the sample if: 1) they were review articles, book chapters and abstracts published in journals; 2) they used pharmacological, physical or psychological stimulation as a stressing agent to observe the HPA axis function. Only articles that fulfilled all the requirements were included in this review.
In the initial assessment, only the abstracts of the articles were read. If the data were not enough, the evaluators assessed the methods and results of the articles. Accepted articles that met all the inclusion criteria were read and analyzed comprehensively.
Analysis of the articles was made qualitatively, according to the method of assessment of cortisol and the division of study groups. After analyzing the articles, results were placed in a table with the following information: authors and year of publication, study goals, sample number and groupings, mean age, main results ( Table 1) . Bias risk was assessed in every article according to the following criteria: sample randomization; cortisol storage duration, temperature, method; assessment kit (Table 2) . Table 1 . Characteristics of the studies that assessed basal cortisol levels and their relationship to symptoms of multiple sclerosis (n = 20). 
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RESULTS
In the initial screening, using the above-mentioned keywords, 87 articles were found in PubMed, 149 in Web of Science and 103 in SCOPUS, 339 articles in total. Out of these, 208 articles were excluded as they were in more than one database and 97 articles did not meet the criteria, leaving 34 articles eligible for assessment. The final process of selection resulted in 20 articles being included. All the articles assessed basal cortisol levels in patients with MS, but only 13 studied the relationship of cortisol with any symptom present in the course of MS. The selection process is shown in Figure 1 .
Assessment of basal cortisol levels in MS
A total of 20 articles investigated cortisol levels in basal conditions in MS ( Table 1 ). The sample size in MS groups ranged from 24 43, 44 to 173 32 individuals, and some studies included control groups without MS 5, 25, 31, 32, 45, 46, 47, 48, 49 . According to Kurtzke's Expanded Disability Status Scale (EDSS), the severity of disease, when assessed, ranged from 1-6.5 points, in individuals from 29-65 years old. In most of the studies (14/20), the patients had not used glucocorticoids, immunomodulators or immunosuppressors for at least one month and, in only three articles, the patients either had never been subjected to pharmacological treatment or used to receive the conventional treatment.
Generally, the studies had three types of general objectives: to verify the effect of treatment, pretreatment or posttreatment on cortisol levels, excluding articles about pharmacological/psychological induction (n = 4); to describe the relationship between cortisol and MS symptoms (n = 13) or another condition (n = 1); and to observe the HPA axis profile in patients with MS (n = 13).
The results of cortisol levels were divergent, many articles (9/20) found higher cortisol levels in MS groups 5, 25, 30, 31, 32, 37, 45, 47, 50 , while others (4/20) showed lower levels 30, 48, 51, 52 or did not differentiate (3/20) from the control group or laboratory thresholds 24, 46, 53 . Some articles did not classify higher or lower cortisol levels (4/20), presenting only the treatment effect 43, 44, 49, 54 , where there was a reduction in levels after interventions or just the relationship with the symptom (1/20) 40 . Five studies did not show a significant correlation between cortisol levels with the duration, progression or severity of MS 5, 24, 32, 47, 52 . One study showed that the cortisol awakening response was associated with the progression of RRMS 45 . There was also a study in which cortisol levels showed a trend to correlation with severity progress in their results 49 . In another study, low cortisol was associated with fast progression and severity of MS 30 .
Types of cortisol samples
Cortisol levels in the articles were assessed from blood, saliva, CSF and urine (Figure 2 ), while most of the studies used serum samples or blood plasma (60%; n = 12). Two articles performed double sampling of cortisol through plasma/urine 32 and serum/CSF 48 , the latter showing a significant difference between the sampling types (CSF: p = 0.0256; serum: p = 0.2886) in different stages of the disease. All the studies that collected saliva investigated the circadian and daytime response of cortisol. No study assessed cortisol from hair samples.
Two postmortem studies included in this review assessed cortisol from CSF and just one in vivo study performed this type of sampling. Storing temperature, if mentioned, ranged between -30º C and -80° C ( Table 2 ). The most-used method of analysis was radioimmunoassay (31.6%; n = 6) and the leastused methods were the competitive binding assay (5.3%; n = 1), and the ultra-high pressure liquid chromatography with mass spectrometry (5.3%, n = 1).
Relationship between cortisol and MS symptoms
A total of 13 articles verified the relationship of cortisol levels with symptoms or comorbidities present in patients with MS 5, 25, 30, 31, 32, 37, 40, 45, 47, 50, 52, 53, 54 . The severity of the disease ranged from 1.3-9 points on the EDSS and the age varied from 32-82 years old. The investigated symptoms were depression 5, 30, 32, 37, 45, 47 , fatigue 25, 32, 40, 50 , urinary dysfunction 52 , female sexual dysfunction 31 , anxiety 54 and obesity 31 .
The most-assessed symptom was depression and three articles found hyperactivity of the HPA axis, correlating high cortisol levels with depression 5, 37, 47 . In contrast, other studies (4/20) did not find a correlation between lower 30 or higher 30,32,45 cortisol levels. Next, fatigue was assessed by four articles, which verified a relationship in patients with a low cortisol awakening response 25 , high levels of cortisol in patients with fatigue compared to controls 50 or did not observe any relationship between fatigue and cortisol 32, 40 .
One study found that there may be a reduction of anxiety symptoms associated with lower cortisol levels 54 . Another study did not find a correlation between cortisol and female sexual dysfunction 53 , however, lower cortisol levels were related to urinary symptoms in both genders 52 . Finally, overweight patients with MS showed a higher release of cortisol when compared with lean patients 32 .
DISCUSSION
This review included 20 articles, which assessed basal cortisol levels and verified their relationship with any type of symptoms and comorbidities (n = 13) in patients with MS. Those studies assessed cortisol through in vivo (18/20 studies) and postmortem (2/20 studies) samples. The mostcommon sample type for assessing cortisol was blood (12/20 studies). Hyperactivity of the HPA axis was observed in most studies (9/20) . The most-investigated symptom was depression (6/13 studies). Among the assessed articles, only three found any correlation between cortisol and the duration and progression of MS.
The results found in the various studies in this review support the HPA axis profile in MS, through measuring released cortisol levels. Generally, in most studies, patients with MS showed higher cortisol levels, indicating hyperactivity of the HPA axis, similar to previously-found results 26, 27 . Although this impairment can be observed in many cases, its causeand-effect relationship remains unknown. However, some hypotheses point out its role in affective disorders, such as depression 55 , which arises during the course of MS. Thus, depressed patients had higher levels of serum cortisol and this hyperactivity may be related to a decreased response of negative feedback mediated by endogenous glucocorticoids 56 .
Alternatively, this hyperactivity of the HPA axis may be linked to the inflammatory activity that happens in active MS. During the inflammatory process, release of cytokines, such as IL-1, IL-6 and TNFα, can perform a modulatory role of the HPA axis, increasing the cortisol release 4 . Alternatively, the HPA axis hypoactivity found in some studies in this review, and decrease in cortisol levels, may be related to the suppression of corticotrophin-releasing hormone neurons that occurs in active lesion in MS 18 . Furthermore, applying the experimental model of autoimmune encephalomyelitis to animal models of MS has demonstrated that the severity and progression of MS is linked to HPA hyporesponsiveness 57, 58 .
Additionally, a postmortem study has shown that lower cortisol levels were associated with larger active lesions and fewer remyelinated plates in humans, while higher cortisol levels were associated with a lower number of active lesions and an increase in plate remyelination 30 . From this perspective, hyperresponsive patients showed fewer lesions highlighted by gadolinium, suggesting a neuroprotection of acute lesions 59 .
Controversially, the HPA axis hyperresponsiveness in MS may be associated with atrophy in the cornu ammonis and dentate gyrus in the hippocampus 47 , and its relationship with symptoms found in MS 5, 31, 37, 47 . Besides this, patients with exacerbations of RRMS have been shown to have higher cortisol levels compared with healthy subjects 45 . As well, lower cortisol levels were found during the acute relapse than in the stable stage of MS 48 .
In this systematic review, many of the studies did not find any relationship between cortisol and MS duration, progression or severity; however, a remarkable number of previous studies have found a relationship between HPA dysfunction and MS progression 18, 21, 29, 59 . The lower cortisol levels found in this review were correlated with the progression of MS, contradicting the fact that lower levels were correlated with more brain lesions 30 .
Although these studies preferentially collected blood serum or plasma, this type of sampling only accounts for acute levels of cortisol release, relative to urine, saliva and CSF samples. Moreover, blood and saliva samples provide a momentary profile, while urine samples refer to cortisol levels over a 24-hour period 60 . However, higher cortisol levels found in studies with CSF samples might have been influenced either by the stress generated in response to lumbar puncture or, in postmortem studies, by the response of the HPA axis to the death process 33, 48 .
Cortisol responses found in these articles refer to acute measurements of the hormone. An alternative to minimizing the interference of stress responses generated by some factors in an ambulatory assessment might be a noninvasive gathering of hair samples. This type of sampling has been considered a reliable method of measuring levels months after exposure to cortisol and it is not influenced by acute stress. Also hair samples can be stored at room temperature 60 .
The difference found between the blood serum sample and the CSF in the results can be explained either by the lower activation of cortisone through 11β-hydroxysteroid dehydrogenase type 1 or by inactivation via 11β-hydroxysteroid dehydrogenase type 2 48 , or can be regulated by the efflux of cortisol from the brain, which provides a balance to cortisol levels in blood and CSF 61 . In contrast, the similarity in levels found between plasma and urine 32 might occur as both sample types provide cortisol levels in the peripherals.
Articles that described assessment characteristics and sample storage did this according to instructions provided by manufacturers of the respective commercial kits. Nevertheless, many studies did not clarify the duration of storage and did not use sample randomization, which made comparison of results among the studies and validity of processing more difficult and increased the bias risk. Similarly, the choice of an accurate and systematic recruitment in case control studies needed to be obtained in the light of data of healthy individuals and patients without MS, who presented for an investigated condition, such as depression. Furthermore, results in some articles were just described as higher or lower, without ever showing mean values found in each group.
Different symptoms are found in MS and they generally tend to worsen as the disease advances. Fatigue is the most common and debilitating symptom, present in more than 80% of the patients with MS 62 . Although it is regarded as a residual symptom of depression 63 , the involvement of cortisol levels remains unclear 25 . The main results encountered in this review on MS did not find any relationship between cortisol and fatigue, corroborating previous evidence that did not observe an influence of cortisol on the fatigue experienced by the patients 39 .
Excessive cortisol in the blood has been related to mood disorders 64 , such as anxiety and depression. Cortisol performs a central role at the onset and during the course of major depression disorder, where higher basal cortisol levels may be found 65 . Patients with MS who had HPA axis hyperactivity may be susceptible to developing depression 66 . In fact, it has been observed that symptoms of depression may precede the onset of specific neurological symptoms during the initial process of MS; however, in spite of the involvement of several epigenetic factors, the etiology of the depression is multifactorial and varies among patients 67 . In this context, higher cortisol levels found in those studies in patients with MS who had anxiety and depression symptoms may have been related to a hyperresponsiveness of the HPA axis found in mood disorders. The lack of correlation with cortisol levels in some studies may have been due to the methodological design and the materials of investigation employed to classify and assess the depressive disorder.
The lower cortisol levels found in urinary dysfunction may indicate a relationship between the hormones of the HPA axis and the deficit of bladder activity inhibition 52 . Results on the relationship between higher cortisol levels and obesity are controversial, and may be justified by several confounding factors that influence cortisol concentration, such as the increase of ACTH release due to copeptin production or the metabolic activity due to the increase of adipose tissue 31 .
One of the limitations of this review is the heterogeneity of the included articles. In fact, there was wide methodological variability, including controlled and uncontrolled studies, as well as randomized and non-randomized essays. Furthermore, the low number of selected articles and the variability of the sample types may have distorted the interpretation and involvement of cortisol with symptoms in MS. Finally, this review did not include a cohort study that evaluated long-term cortisol in patients with MS, for further understanding of its involvement in the progression of the disease.
In conclusion, this systematic review included an overview of studies that investigated basal cortisol levels and symptoms in MS. The results found pointed to a cortisol level dysfunction and some involvement with symptoms, mainly depression, present in MS. Although there was a satisfactory number of studies and promising investigations on the subject, the results still did not present a consensus on the activity of the HPA axis and cortisol release in patients with MS. However, the majority of studies indicated higher cortisol levels associated with the progression and severity of MS.
Differences related to the type of sample were found among both peripheral and central samples, though the number of studies was not enough to clarify the validity and differences among the sample types. The divergences found were limited to lack of methodological consistency, sample size and standardization, such as, for example, the duration of the disease and type of MS, as well as the evaluation types used in some studies. Because of this, further investigations are necessary to better understand the role of cortisol in MS, such as: (1) observation of the cortisol release in peripheral and central samples; (2) verification of the role of cortisol as a trigger for relapses and several motor, cognitive and behavioral symptoms that arise with the disease; and (3) elaboration on standardized methods that control the influence of the circadian cycle on this hormone.
